Wacker Biotech will begin GMP production of Phase I clinical material of Actym’s therapeutic candidate at its site in Amsterdam using its LIBATEC® technology. Both companies have already been working on technology transfer and initiation of scale-up production of ACTM-838, which is Actym’s lead clinical development candidate for solid tumor therapy and is on the company's immunotherapy platform called STACT.
/PRNewswire/ We are pleased to announce that Actym Therapeutics President and CEO, Dr. Christopher Thanos, has been named one of the "Top 25 Biotech CEOs.